Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PCSA
PROCESSA PHARMACEUTICALS, INC.
NASDAQ
$2.08
▼ DOWN 3.03% (-0.07)

KEY STATISTICS

Market Cap$5.76 M
52w High$14.25
52w Low$1.67
Dividend Yield—
Frequency—
P/E-0.07
Volume75.97K
Shares Out.2.77M

COMPANY

LEADERSHIP

George K. Ng
CHIEF EXECUTIVE
George K. Ng

COMPENSATION 2026

Salary$400,000
Stock Awards$50,688
Incentive Plan Pay$0
All Other Comp.$23,930
Total$673,303

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 7, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
12

PRICE TARGET

Target High$225.00
Target Low$225.00
Target Median$225.00
Target Consensus$225.00

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.—
OCT
29
THU

SPLIT RECORD

DATETYPERATIO
2025-12-17Reverse1:25
2024-01-22Reverse1:20
2019-12-23Reverse1:7
2017-12-26Reverse1:7
2017-12-08Reverse1:7

PRICE

$2.08 ▼ DOWN 3.03% (−$0.07)
OVERLAYS
$2.02$2.10$2.189:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM2.08

About Processa Pharmaceuticals, Inc.

https://www.processapharmaceuticals.com ↗

Processa Pharmaceuticals is a clinical-stage biopharma developing drug candidates like PCS499, PCS12852, and others for unmet medical needs in cancer, gastrointestinal, and inflammatory conditions in the U.S.

INDUSTRY

Biotechnology

A PRODUCT PROCESSA PHARMACEUTICALS, INC. IS KNOWN FOR

NGC-Cap (PCS6422)
NGC-Cap (PCS6422)

NGC-Cap is Processa's lead Phase 2 clinical-stage chemotherapy candidate targeting metastatic breast cancer, designed to enhance capecitabine's efficacy and safety by altering its metabolism, with an interim analysis expected in Q1 2026.

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 12.7K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Ng George K
Sale · 1.6K shares
2026-08-08
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Ng George K
Purchase · 1.6K shares
2026-08-08
★
DIRECTOR
GUJRATHI SHEILA
Purchase · 70.8K shares
2026-07-28
★
DIRECTOR
GUJRATHI SHEILA
Purchase · 12.3K shares
2026-07-28

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
PALI$2.10COMPARE
BCTX$4.07COMPARE
ALLR$1.42COMPARE
CTXR$0.60COMPARE
MBRX$0.59COMPARE
CRIS$1.58COMPARE